GLP-1 vs Omentin-1
Head-to-head comparison of GLP-1 (Glucagon-like peptide-1 (7-36 amide)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
| Property | GLP-1 | Omentin-1 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Glucagon-like peptide-1 (7-36 amide) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 3297 Da | ~35 kDa |
| Half-Life | 1-2 minutes | hours |
| Amino Acids | 30 | 313 |
| Typical Dose | Research-only: 0.1-1.0 pmol/kg/min | No approved human dose; research use only |
| Route | Intravenous/Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 82 |
| Research Status | Pre-clinical | Pre-clinical |
GLP-1 Benefits
- ✓beta-cell protection
- ✓improved insulin secretion
- ✓slower gastric emptying
- ✓lower postprandial glucose
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
GLP-1 Dosing
0.1-1.0 pmol/kg/min IV infusion in research|0.5-10 nM in vitro|continuous delivery in animal studies
Omentin-1 Dosing
not established|not established
GLP-1 Side Effects
- ⚠nausea at pharmacologic exposure
- ⚠tachyphylaxis with continuous exposure
- ⚠headache
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
GLP-1
Native GLP-1 has a very short half-life because of rapid DPP-4 cleavage, so it is mainly used as a mechanistic research peptide. Across animal and cellular studies it reduces beta-cell apoptosis, improves insulin gene expression, and enhances islet resilience.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.